Pharmaceutical Technology

AUGUST 9, 2022

Health Canada has accepted the New Drug Submission (NDS) of Endo International subsidiary Paladin Labs for cenobamate tablets as an adjunctive treatment to manage partial-onset seizures in adult epilepsy patients. In the clinical development programme, 1,944 epilepsy patients received cenobamate treatment.

Labelling 98

Labelling 98

Pharmaceutical Technology

FEBRUARY 8, 2024

OPL-044 is under clinical development by Overseas Pharmaceuticals and currently in Phase I for Epilepsy.

40

40

Pharmaceutical Technology

MAY 12, 2023

Angelini Pharma has entered an exclusive global development and commercialisation deal with JCR Pharmaceuticals to develop and commercialise new biologic therapies to treat epilepsy. Angelini Pharma CEO Jacopo Andreose stated: “Epilepsy is one of the most prevalent chronic neurological diseases.

52

52

Pharmaceutical Technology

MAY 9, 2023

Biotechnology company Neuro3 Therapeutics has signed an exclusive worldwide licence and option agreement with pharmaceutical firm Lundbeck to develop and commercialise clinical stage KCNQ2 activators. The company will also handle the further development of these programmes through clinical proof-of-concept (PoC).

52

52

European Pharmaceutical Review

SEPTEMBER 8, 2022

“The results consistently showed a clinical and statistical increase in the time between use of intranasal diazepam, Valtoco, over time. The trial enrolled participants aged six to 65 years, in adult patients enrolled, Quality of Life in Epilepsy scores were maintained with increased SEIVALs. days in Period 1 (day 1-90) to 26.8

Medical Schools 93

Medical Schools 93

pharmaphorum

OCTOBER 13, 2021

Spark Therapeutics has secured the exclusive rights to CombiGene’s CG01 therapy, which aims to treat drug resistant focal epilepsy, in a deal worth $8.5m in advance with further payments due on reaching clinical milestones. million excluding royalties and up to $50 million at preclinical and clinical milestones. to SEK14.10

59

59

pharmaphorum

OCTOBER 26, 2022

German specialty drugmaker Neuraxpharm has licensed commercial rights in Europe to a wearable device developed by Spanish start-up mjn-neuro that is designed to warn a person with epilepsy about an impending seizure. mjn-SERAS already has a CE mark in Europe and is currently in clinical testing, with results due in 2023.

Communication 64

Communication 64

pharmaphorum

MAY 18, 2022

Unmet needs in epilepsy. In epilepsy research, for instance, a lot of progress has been made over recent years that has helped improve the lives of many people living with the disease. Beyond epilepsy, there is a range of further neurological disorders that are becoming increasingly well-understood.

Pharmaceutical Companies 92

Pharmaceutical Companies Pharmaceutical Companies Immunization 92

European Pharmaceutical Review

DECEMBER 8, 2023

Cerevel’s pipeline includes multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson’s disease, and mood disorders. Gonzalez, chairman and chief executive officer of AbbVie.

FDA 99

FDA 99

Blog: Ask a Student Pharmacist

OCTOBER 18, 2023

Our Team dtadege Wed, 10/18/2023 - 18:09 Left to right: Marcia Terluk, Mohamed Fayed, Jaehyeok Roh, Jim Cloyd, Adeboye Bamgboye, Chenxu Li, Bob Kriel, Emily Letscher, Lisa Coles, Usha Mishra, Mohamed Duklef, Reena Kartha James Cloyd III, PharmD Director, Center for Orphan Drug Research Email: cloyd001@umn.edu Office Phone: 612-624-4609 Faculty and (..)

52

52

STAT

DECEMBER 7, 2023

 With this latest deal, AbbVie will acquire several clinical-stage molecules for Parkinson’s, schizophrenia, and epilepsy, among other disorders, many of which previously belonged to one of its biggest rivals. Continue to STAT+ to read the full story…

99

99

Pharmaceutical Technology

JUNE 1, 2023

According to the clinical trial evidence, rimegepant works better to reduce the number of episodic migraines in patients who have previously tried three preventive treatments, compared to a dummy treatment. Up to 145,000 people in England will have the option to choose this treatment.

98

98

PharmaShots

MAY 11, 2023

upon achievement of development & commercial milestones along with royalties on post-approval net sales Following the pre-clinical development phase, Angelini Pharma will have an exclusive license for the clinical development of therapeutic candidates & their commercialization outside of Japan.

FDA 40

FDA 40

European Pharmaceutical Review

DECEMBER 20, 2022

Commenting on fenfluramine, an oral solution developed by biopharma UCB, this “positive CHMP opinion is a significant regulatory milestone towards providing a new treatment option [for] this rare epilepsy in the EU,” explained Mike Davis, Head of Global Epilepsy & Rare Syndromes, UCB.

Labelling 89

Labelling 89

Board Vitals - Pharmacist

JANUARY 11, 2024

The 19-month-old girl presented with baffling symptoms that mimicked those of encephalitis or epilepsy. Pharmaceutical industry: Pharmacists may design or conduct clinical drug trials and help to develop new drugs. Luckily, an on-duty hospital nurse had read bestselling mystery writer Agatha Christie’s 1961 novel, “The Pale Horse.”

Retail Drug Stores 98

Retail Drug Stores Hospitals Insurance Patient Care 98

European Pharmaceutical Review

FEBRUARY 21, 2023

Notably Wakeley explained: “new R&D is opening up the potential of these medicines in new indications, eg, epilepsy and multiple sclerosis (MS).” Arthur Wakeley What data can you share about clinical trials for cannabis-based medicines? James Short What were the key challenges for Celadon during the GMP registration process?

Pharmaceutical Companies 131

Pharmaceutical Companies Pharmaceutical Companies Compounding 131

European Pharmaceutical Review

JUNE 1, 2023

Clinical trial evidence shows that the oral migraine treatment works better than a placebo for reducing the number of episodic migraines in people who have already tried three preventive treatments. These can have significant side-effects and can be ineffective for some people.

87

87

The Checkup by Singlecare

DECEMBER 5, 2023

Gabapentin (Neurontin, Horizant) Most popular prescription in Connecticut and Virginia Gabapentin coupons Gabapentin is an anticonvulsant used to treat seizures in individuals with epilepsy, as well as nerve pain caused by shingles. of the population in the United States has epilepsy. Approximately 1.2%

Mayo Clinic 105

Mayo Clinic Department of Veterans Affairs Labelling Medical Schools 105

The Checkup by Singlecare

FEBRUARY 21, 2024

The FDA has not approved its use for this indication, and there are still ongoing clinical trials to determine its effectiveness and risk profile. Patients with epilepsy (seizures) and are on medication for this condition should exercise caution when using hydroxychloroquine due to its potential to lower the seizure threshold.

Dosage 52

Dosage Documentation FDA Labelling 52

Pharmaceutical Technology

MARCH 1, 2023

NPT-2042 is under clinical development by NeuroPro Therapeutics and currently in Phase I for Seizures. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is administered as soft-gelatin capsules administered through orally route.

40

40

pharmaphorum

NOVEMBER 25, 2022

Dubbed ONCOVALUE, the initiative will set up a consortium that will develop an artificial intelligence (AI) platform that will be used for routine collection and analysis of clinical data on new oncology medicines to support their assessment by regulators and health technology assessment (HTA) agencies.

Hospitals 90

Hospitals 90

pharmaphorum

NOVEMBER 3, 2020

Ring Chromosome 20 Syndrome, or (R)20, is an ultra-rare form of epilepsy with a devastating impact – yet despite huge leaps forward in gene sequencing in recent years, diagnoses are going down instead of up. There are no clinical practice guidelines, meaning doctors treat on a case-by-case basis. Raising awareness, offering support.

Hospitals 118

Hospitals 118

pharmaphorum

SEPTEMBER 9, 2020

However, in 2013, Charlie’s life changed dramatically when his daughter, who has cerebral palsy, was also diagnosed with a catastrophic form of epilepsy called West Syndrome. “My She was originally diagnosed with gastrointestinal reflux – which is a common misdiagnosis for infants with epilepsy.

Hospitals 102

Hospitals 102

pharmaphorum

SEPTEMBER 23, 2021

A study has found that listening to a specially composed music track can achieve “clinically significant” reductions in pain intensity and unpleasantness, according to the researchers behind the work.

136

136

The Checkup by Singlecare

DECEMBER 6, 2023

Food and Drug Administration (FDA) to treat epilepsy and prevent various types of seizures. Key takeaways: Topiramate is a prescription medicine used to treat epilepsy and migraine headaches and as an aid for weight loss. Continue reading to learn more about topiramate and its potential interactions.

Labelling 52

Labelling Mayo Clinic FDA Dosage 52

European Pharmaceutical Review

APRIL 3, 2023

It relies partly on results of pre-clinical tests and clinical trials of an already authorised reference product and in part on new data.

Vaccines 89

Vaccines Chemotherapy Generic Medicine 89

pharmaphorum

SEPTEMBER 9, 2020

However, in 2013, Charlie’s life changed dramatically when his daughter, who has cerebral palsy, was also diagnosed with a catastrophic form of epilepsy called West Syndrome. “My She was originally diagnosed with gastrointestinal reflux – which is a common misdiagnosis for infants with epilepsy.

Hospitals 80

Hospitals 80

pharmaphorum

OCTOBER 20, 2021

For patients with epilepsy, traumatic brain injuries, or a brain tumour, an implant used short-term can effectively analyse brain activity and determine the appropriate treatment path. “Suppose the patient is given a drug for epilepsy. Implant applications. ” Detecting secondary brain injury . About the author .

97

97

pharmaphorum

SEPTEMBER 14, 2021

The first patient has received a low dose of Beckley Psytech’s psychedelic medicine psilocybin in a clinical trial for short-lasting unilateral neuralgiform headache attacks (SUNHA), a rare disorder. The UK company says that SUNHA is a debilitating condition that is estimated to affect 40,000 patients in US and Europe.

Compounding 105

Compounding Labelling 105

European Pharmaceutical Review

MARCH 6, 2023

Keen to learn more about lecanemab’s promising potential to treat the disease, EPR caught up with Dr Michael Irizarry, Senior Vice President of Clinical Research and Deputy Chief Clinical Officer of Alzheimer’s Disease and Brain Health at Eisai. Lecanemab treatment [demonstrated] a 27 percent slowing of [clinical] decline.”

Dosage 80

Dosage FDA 80

The Checkup by Singlecare

JANUARY 17, 2024

People with heart disease and epilepsy may not be able to take TCAs. They work by inhibiting the reuptake of serotonin and norepinephrine in varying degrees, depending on which specific medication is used. Side effects can include dizziness, constipation, and dry mouth.

Dosage 98

Dosage FDA 98

pharmaphorum

MARCH 2, 2022

The total value of the deal could rise to $1 billion, dependent on whether Syndesi’s SV2A drugs – headed by early-stage clinical candidate SDI-118 – progress in development and reach the market. Syndesi is its second acquisition in the neuroscience area in the last 12 months.

52

52

pharmaphorum

JULY 20, 2022

Armed with a $100 million second-round financing, CAMP4 Therapeutics is preparing to start the first clinical trial of a drug targeting regulatory RNA (regRNA) molecules that can be used to fine-tune the expression of genes. ” The post CAMP4 raises $100m to take lead RNA drugs into clinic appeared first on.

Compounding 52

Compounding 52

PharmaShots

MAY 12, 2023

Difficile Infection at DDW 2023 Date: May 08, 2023 | Tags: Seres Therapeutics, Nestlé Health Science, Vowst, Recurrence of C.

FDA 40

FDA Chemotherapy Immunization Hospitals 40

pharmaphorum

OCTOBER 12, 2021

The deal will diversify Supernus’ revenues and reduce its reliance on Trokendi XR (topiramate), a drug for migraine prevention and epilepsy that currently accounts for around half its revenues. The post Supernus bulks up its Parkinson’s portfolio with Adamas takeover appeared first on.

FDA 97

FDA 97

Board Vitals - Pharmacist

AUGUST 26, 2022

Neuroscience and mechanism of disease 22-28% Clinical aspects of neurologic disease 17-23% Diagnostic procedures 17-23% Treatment/Management 22-28% Interpersonal and communication skills 2-3% Professionalism 2-3% Practice-based learning and improvement 2-3% Systems-based practice 2-3%. Dimension 2 : Physician Competencies and Mechanisms.

Communication 98

Communication 98

pharmaphorum

NOVEMBER 24, 2022

More than two years on, the EU medicines regulator has now selected the first set of data partners to collaborate with DARWIN EU, which focuses on real-world evidence collected on a patient’s health status or delivery of healthcare from a variety of sources, other than conventional clinical trials.

Documentation 52

Documentation Insurance Hospitals 52